Federal regulators recently approved Pfizer's new Xeljanz treatment for rheumatoid arthritis. Xeljanz was approved for patients with moderate to severe rheumatoid arthritis who did not benefit from the oral treatment methotrexate.
More than one-third of 93,000 Medicare managed care enrollees who received care for rheumatoid arthritis in recent years did not receive recommended drugs, according to researchers. In addition, the quality of drug treatments varied among geographic areas, socio-economic groups and health plans. Study results appeared in Wednesday's issue of the Journal of the American Medical Association.